PPARδ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis
| Autor: | Kunal R. Sampat, Audrey S. Dickey, Cynthia Hsu, Ronald M. Evans, Eliezer Masliah, Stephen K. Gilmore-Hall, Christopher A. Ross, Dafne N. Sanchez, Kohta Ohnishi, Nicole S. Lomas, Donald C. Lo, Albert R. La Spada, Janice M. Nguyen, Nicolas Arbez, April L. Flores, Weiwei Fan, Martin Arreola, Michael J. Van Kanegan, Sergey S Akimov |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Agonist Tetrahydronaphthalenes medicine.drug_class Retinoid X receptor Pharmacology Neuroprotection Article Rats Sprague-Dawley 03 medical and health sciences Mice medicine Animals Homeostasis Humans PPAR delta Receptor Muscle Skeletal Transcription factor Bexarotene Neurons business.industry Reverse Transcriptase Polymerase Chain Reaction Neurodegeneration General Medicine medicine.disease Rats 030104 developmental biology Huntington Disease Mitochondrial biogenesis Gene Expression Regulation business medicine.drug Signal Transduction |
| Zdroj: | Science translational medicine. 9(419) |
| ISSN: | 1946-6242 |
| Popis: | Neurons must maintain protein and mitochondrial quality control for optimal function, an energetically expensive process. The peroxisome proliferator–activated receptors (PPARs) are ligand-activated transcription factors that promote mitochondrial biogenesis and oxidative metabolism. We recently determined that transcriptional dysregulation of PPARδ contributes to Huntington’s disease (HD), a progressive neurodegenerative disorder resulting from a CAG-polyglutamine repeat expansion in the huntingtin gene. We documented that the PPARδ agonist KD3010 is an effective therapy for HD in a mouse model. PPARδ forms a heterodimer with the retinoid X receptor (RXR), and RXR agonists are capable of promoting PPARδ activation. One compound with potent RXR agonist activity is the U.S. Food and Drug Administration–approved drug bexarotene. We tested the therapeutic potential of bexarotene in HD and found that bexarotene was neuroprotective in cellular models of HD, including medium spiny-like neurons generated from induced pluripotent stem cells (iPSCs) derived from patients with HD. To evaluate bexarotene as a treatment for HD, we treated the N171-82Q mouse model with the drug and found that bexarotene improved motor function, reduced neurodegeneration, and increased survival. To determine the basis for PPARδ neuroprotection, we evaluated metabolic function and noted markedly impaired oxidative metabolism in HD neurons, which was rescued by bexarotene or KD3010. We examined mitochondrial and protein quality control in cellular models of HD and observed that treatment with a PPARδ agonist promoted cellular quality control. By boosting cellular activities that are dysfunctional in HD, PPARδ activation may have therapeutic applications in HD and potentially other neurodegenerative diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|